These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 29779045)

  • 61. Corticostriatal covariance patterns of 6-[18F]fluoro-L-dopa and [18F]fluorodeoxyglucose PET in Parkinson's disease.
    Kaasinen V; Maguire RP; Hundemer HP; Leenders KL
    J Neurol; 2006 Mar; 253(3):340-8. PubMed ID: 16222426
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism.
    Schreckenberger M; Hägele S; Siessmeier T; Buchholz HG; Armbrust-Henrich H; Rösch F; Gründer G; Bartenstein P; Vogt T
    Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1128-35. PubMed ID: 15042325
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Transcranial sonography for the discrimination of idiopathic Parkinson's disease from the atypical parkinsonian syndromes.
    Bouwmans AE; Vlaar AM; Srulijes K; Mess WH; Weber WE
    Int Rev Neurobiol; 2010; 90():121-46. PubMed ID: 20692498
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Positron emission tomography imaging of tau pathology in progressive supranuclear palsy.
    Coakeley S; Cho SS; Koshimori Y; Rusjan P; Harris M; Ghadery C; Kim J; Lang AE; Wilson A; Houle S; Strafella AP
    J Cereb Blood Flow Metab; 2017 Sep; 37(9):3150-3160. PubMed ID: 28155586
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.
    Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J
    J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease.
    Drzezga A; Altomare D; Festari C; Arbizu J; Orini S; Herholz K; Nestor P; Agosta F; Bouwman F; Nobili F; Walker Z; Frisoni GB; Boccardi M;
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1487-1496. PubMed ID: 29756163
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The role of molecular imaging in assessing degenerative parkinsonism - an updated review.
    Nicastro N; Garibotto V; Burkhard PR
    Swiss Med Wkly; 2018; 148():w14621. PubMed ID: 29698545
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Abnormal metabolic networks in atypical parkinsonism.
    Eckert T; Tang C; Ma Y; Brown N; Lin T; Frucht S; Feigin A; Eidelberg D
    Mov Disord; 2008 Apr; 23(5):727-33. PubMed ID: 18186116
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism.
    Feigin A; Antonini A; Fukuda M; De Notaris R; Benti R; Pezzoli G; Mentis MJ; Moeller JR; Eidelberg D
    Mov Disord; 2002 Nov; 17(6):1265-70. PubMed ID: 12465066
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Neuropathological correlation supports automated image-based differential diagnosis in parkinsonism.
    Schindlbeck KA; Gupta DK; Tang CC; O'Shea SA; Poston KL; Choi YY; Dhawan V; Vonsattel JP; Fahn S; Eidelberg D
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3522-3529. PubMed ID: 33839891
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration-[18F]FDG-PET.
    Liepelt I; Reimold M; Maetzler W; Godau J; Reischl G; Gaenslen A; Herbst H; Berg D
    Mov Disord; 2009 Jul; 24(10):1504-11. PubMed ID: 19489069
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The phase value of putamen measured by susceptibility weighted images in Parkinson's disease and in other forms of Parkinsonism: a correlation study with F18 FP-CIT PET.
    Kwon GH; Jang J; Choi HS; Hwang EJ; Jung SL; Ahn KJ; Kim BS; Yoo IeR; Kim SH; Haacke EM
    Acta Radiol; 2016 Jul; 57(7):852-60. PubMed ID: 26377263
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Clinical utility of (18)F-DOPA-PET in movement disorders. A systematic review].
    Puñal-Riobóo J; Serena-Puig A; Varela-Lema L; Alvarez-Páez AM; Ruano-Ravina A
    Rev Esp Med Nucl; 2009; 28(3):106-13. PubMed ID: 19558950
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Use of deep learning-based radiomics to differentiate Parkinson's disease patients from normal controls: a study based on [
    Sun X; Ge J; Li L; Zhang Q; Lin W; Chen Y; Wu P; Yang L; Zuo C; Jiang J
    Eur Radiol; 2022 Nov; 32(11):8008-8018. PubMed ID: 35674825
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson's Disease and Atypical Parkinsonian Syndromes.
    Fujita H; Suzuki K; Numao A; Watanabe Y; Uchiyama T; Miyamoto T; Miyamoto M; Hirata K
    PLoS One; 2016; 11(11):e0165869. PubMed ID: 27812167
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound.
    Behnke S; Berg D; Naumann M; Becker G
    J Neurol Neurosurg Psychiatry; 2005 Mar; 76(3):423-5. PubMed ID: 15716540
    [TBL] [Abstract][Full Text] [Related]  

  • 79. 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis.
    Kyzas PA; Evangelou E; Denaxa-Kyza D; Ioannidis JP
    J Natl Cancer Inst; 2008 May; 100(10):712-20. PubMed ID: 18477804
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Whole-Body
    Sheikhbahaei S; Marcus CV; Fragomeni RS; Rowe SP; Javadi MS; Solnes LB
    J Nucl Med; 2017 Jul; 58(7):1031-1036. PubMed ID: 27980049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.